Lodo Therapeutics seeks to realize the vision of researcher and co-founder Sean Brady, Ph.D., focusing on the discovery, biosynthesis, and characterization of new, genetically-encoded small molecules from microbial sources, particularly from uncultured soil bacteria and the human microbiome.
Market
Pharmaceuticals
Location
New York,
NY,
USA
Coinvestors
AbbVie Biotech Ventures, Accelerator, Alexandria Real Estate Equities, ARCH Venture Partners, Eli Lilly and Company, Harris & Harris Group, Innovate NY Fund, Johnson & Johnson Development Corporation (JJDC), Pfizer Strategic Investments Group, The Partnership for New York City Fund, Watson Fund, WuXi Corporate Venture Fund